Synonym
(R)-Citalopram oxalate;
IUPAC/Chemical Name
(R)-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile oxalate
InChi Key
KTGRHKOEFSJQNS-VEIFNGETSA-N
InChi Code
InChI=1S/C20H21FN2O.C2H2O4/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;3-1(4)2(5)6/h4-9,12H,3,10-11,14H2,1-2H3;(H,3,4)(H,5,6)/t20-;/m1./s1
SMILES Code
N#CC1=CC2=C([C@](C3=CC=C(F)C=C3)(CCCN(C)C)OC2)C=C1.O=C(O)C(O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
414.43
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Kirino E. Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Prefer Adherence. 2012;6:853-61. doi: 10.2147/PPA.S22495. Epub 2012 Dec 4. PubMed PMID: 23271894; PubMed Central PMCID: PMC3526882.
2: Alarfaj NA, Aly FA, Al-Qahtany AA. Flow-injection chemiluminescence and electrogenerated chemiluminescence determination of escitalopram oxalate in tablet form. Luminescence. 2013 Jan-Feb;28(1):84-92. doi: 10.1002/bio.2372. Epub 2012 May 4. PubMed PMID: 22555899.
3: de Diego HL, Bond AD, Dancer RJ. Formation of solid solutions between racemic and enantiomeric citalopram oxalate. Chirality. 2011 May;23(5):408-16. doi: 10.1002/chir.20943. Epub 2011 Apr 6. PubMed PMID: 21472783.
4: Li J, Tian Y, Zhang ZJ, Wang N, Ren X, Chen Y. Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. Arzneimittelforschung. 2009;59(5):228-32. doi: 10.1055/s-0031-1296389. PubMed PMID: 19537522.
5: Bhatt J, Jangid A, Shetty R, Shah B, Kambli S, Subbaiah G, Singh S. Rapid and sensitive liquid chromatography-mass spectrometry method for determination of ropinirole in human plasma. J Pharm Biomed Anal. 2006 Mar 18;40(5):1202-8. Epub 2005 Nov 11. PubMed PMID: 16289706.
6: Pullar IA, Boot JR, Broadmore RJ, Eyre TA, Cooper J, Sanger GJ, Wedley S, Mitchell SN. The role of the 5-HT1D receptor as a presynaptic autoreceptor in the guinea pig. Eur J Pharmacol. 2004 Jun 16;493(1-3):85-93. PubMed PMID: 15189767.
7: Burke WJ. Escitalopram. Expert Opin Investig Drugs. 2002 Oct;11(10):1477-86. Review. PubMed PMID: 12387707.
